DE60041119D1 - Verfahren zur präsentation von (poly)peptiden/proteinen auf bakteriophagenpartikeln via disulfidbindungen - Google Patents

Verfahren zur präsentation von (poly)peptiden/proteinen auf bakteriophagenpartikeln via disulfidbindungen

Info

Publication number
DE60041119D1
DE60041119D1 DE60041119T DE60041119T DE60041119D1 DE 60041119 D1 DE60041119 D1 DE 60041119D1 DE 60041119 T DE60041119 T DE 60041119T DE 60041119 T DE60041119 T DE 60041119T DE 60041119 D1 DE60041119 D1 DE 60041119D1
Authority
DE
Germany
Prior art keywords
poly
proteins
peptides
disulpide
bindings
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60041119T
Other languages
German (de)
English (en)
Inventor
Corinna Loehning
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Morphosys AG
Original Assignee
Morphosys AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26070571&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE60041119(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Morphosys AG filed Critical Morphosys AG
Application granted granted Critical
Publication of DE60041119D1 publication Critical patent/DE60041119D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B40/00—Libraries per se, e.g. arrays, mixtures
    • C40B40/02—Libraries contained in or displayed by microorganisms, e.g. bacteria or animal cells; Libraries contained in or displayed by vectors, e.g. plasmids; Libraries containing only microorganisms or vectors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1037—Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/10011—Details dsDNA Bacteriophages
    • C12N2795/10022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Processes Of Treating Macromolecular Substances (AREA)
DE60041119T 1999-07-20 2000-07-20 Verfahren zur präsentation von (poly)peptiden/proteinen auf bakteriophagenpartikeln via disulfidbindungen Expired - Lifetime DE60041119D1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP99114072 1999-07-20
EP00103551 2000-02-18
PCT/EP2000/006968 WO2001005950A2 (en) 1999-07-20 2000-07-20 Methods for displaying (poly)peptides/proteins on bacteriophage particles via disulfide bonds

Publications (1)

Publication Number Publication Date
DE60041119D1 true DE60041119D1 (de) 2009-01-29

Family

ID=26070571

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60041119T Expired - Lifetime DE60041119D1 (de) 1999-07-20 2000-07-20 Verfahren zur präsentation von (poly)peptiden/proteinen auf bakteriophagenpartikeln via disulfidbindungen

Country Status (13)

Country Link
US (3) US6753136B2 (enExample)
EP (2) EP1990409A3 (enExample)
JP (1) JP4312403B2 (enExample)
AT (1) ATE417925T1 (enExample)
AU (1) AU781396B2 (enExample)
CA (1) CA2347973C (enExample)
DE (1) DE60041119D1 (enExample)
DK (1) DK1144607T5 (enExample)
ES (1) ES2327382T3 (enExample)
IL (2) IL142025A0 (enExample)
NO (1) NO331199B1 (enExample)
PT (1) PT1144607E (enExample)
WO (1) WO2001005950A2 (enExample)

Families Citing this family (136)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6472147B1 (en) * 1999-05-25 2002-10-29 The Scripps Research Institute Methods for display of heterodimeric proteins on filamentous phage using pVII and pIX, compositions, vectors and combinatorial libraries
WO2001023619A1 (en) * 1999-09-29 2001-04-05 Xenoport, Inc. Compounds displayed on replicable genetic packages and methods of using same
US7037706B1 (en) 1999-09-29 2006-05-02 Xenoport, Inc. Compounds displayed on replicable genetic packages and methods of using same
US8288322B2 (en) * 2000-04-17 2012-10-16 Dyax Corp. Methods of constructing libraries comprising displayed and/or expressed members of a diverse family of peptides, polypeptides or proteins and the novel libraries
DK1276855T3 (da) * 2000-04-17 2012-11-26 Dyax Corp Fremgangsmåde til konstruktion af visningsbiblioteker over genetiske pakker for medlemmer af en diversificeret peptidfamilie
US20030119056A1 (en) 2000-12-18 2003-06-26 Ladner Robert Charles Focused libraries of genetic packages
US7229757B2 (en) 2001-03-21 2007-06-12 Xenoport, Inc. Compounds displayed on icosahedral phage and methods of using same
US6833441B2 (en) 2001-08-01 2004-12-21 Abmaxis, Inc. Compositions and methods for generating chimeric heteromultimers
US7202045B2 (en) * 2001-09-19 2007-04-10 Regents Of The University Of Michigan Detection and treatment of cancers of the lung
US7175983B2 (en) * 2001-11-02 2007-02-13 Abmaxis, Inc. Adapter-directed display systems
US8206977B2 (en) * 2002-07-30 2012-06-26 Morphosys Ag Tricistronic vectors and uses therefor
US20040067532A1 (en) 2002-08-12 2004-04-08 Genetastix Corporation High throughput generation and affinity maturation of humanized antibody
NZ570811A (en) 2002-11-09 2009-11-27 Immunocore Ltd T cell receptor display
WO2004063337A2 (en) 2003-01-07 2004-07-29 Dyax Corporation Kunitz domain library
ES2541436T3 (es) 2004-02-06 2015-07-20 Morphosys Ag Anticuerpos humanos anti-CD38 y usos para ellos
US9200061B2 (en) 2004-02-06 2015-12-01 Morpho Sys AG Generation and profiling of fully human HuCAL gold®-derived therapeutic antibodies specific for human CD3i
US8263746B2 (en) 2004-02-06 2012-09-11 Morphosys Ag Anti-CD38 human antibodies and uses thereof
EP1855723B1 (en) 2005-03-08 2013-05-22 Ramot at Tel-Aviv University Ltd. Targeted drug-carrying bacteriophages
BRPI0610796B8 (pt) 2005-05-18 2021-05-25 Morphosys Ag anticorpo humano ou humanizado isolado, ou um fragmento fab ou scfv do mesmo, sequência de ácidos nucleicos, vetor, e, uso de um anticorpo
US8114964B2 (en) 2005-05-19 2012-02-14 Centocor, Inc. Anti-MCP-1 antibodies, compositions, methods and uses
TW200745162A (en) 2005-05-24 2007-12-16 Morphosys Ag Generation and profiling of fully human hucal gold-derived therapeutic antibodies specific for human CD38
AR055191A1 (es) 2005-10-12 2007-08-08 Morphosys Ag Generacion y caracterizacion de anticuerpos terapeuticos derivados de hucal- gold totalmente humanos especificos para el cd38 humano
DE502005009389D1 (de) 2005-11-09 2010-05-20 Morphosys Ag Identifizierung und charakterisierung von funktionsblockierenden anti-ed-b-fibronektin antikörpern
DOP2006000277A (es) 2005-12-12 2007-08-31 Bayer Pharmaceuticals Corp Anticuerpos anti mn y métodos para su utilización
US8273688B2 (en) * 2005-12-20 2012-09-25 Morphosys Ag Collection of HCDR3 regions and uses therefor
MX2008012485A (es) 2006-03-30 2008-10-10 Novartis Ag Composiciones y metodos de uso para anticuerpos de c-met.
JP2009535063A (ja) 2006-05-04 2009-10-01 アブマクシス・インコーポレイテツド 異種間及び複数種提示系
AU2007307260B2 (en) 2006-07-05 2013-02-28 Catalyst Biosciences, Inc. Protease screening methods and proteases identified thereby
US8759087B2 (en) 2006-12-12 2014-06-24 Morpho Sys AG Internalization
WO2009024593A1 (en) * 2007-08-21 2009-02-26 Morphosys Ag Improved methods for the formation of disulphide bonds
WO2009028639A1 (ja) 2007-08-30 2009-03-05 Daiichi Sankyo Company, Limited 抗ｅｐｈａ２抗体
EP3753947A1 (en) 2007-09-14 2020-12-23 Adimab, LLC Rationally designed, synthetic antibody libraries and uses therefor
US8877688B2 (en) 2007-09-14 2014-11-04 Adimab, Llc Rationally designed, synthetic antibody libraries and uses therefor
TWI489993B (zh) 2007-10-12 2015-07-01 Novartis Ag 骨硬化素（ｓｃｌｅｒｏｓｔｉｎ）抗體組合物及使用方法
MX2010005603A (es) 2007-11-26 2010-08-02 Bayer Schering Pharma Ag Anticuerpos antimesotelina y usos de los mismos.
ES2509959T5 (en) 2008-02-05 2024-12-19 Bicyclerd Ltd Methods and compositions
US9873957B2 (en) * 2008-03-13 2018-01-23 Dyax Corp. Libraries of genetic packages comprising novel HC CDR3 designs
US10485879B2 (en) 2008-04-15 2019-11-26 Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, National Institutes Of Health Plasma cell cytokine vehicle containing fusion proteins for targeted introduction of siRNA into cells and tissues
WO2009129281A2 (en) 2008-04-15 2009-10-22 Government Of The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Compositions and methods for delivering inhibitory oligonucleotides
US9388510B2 (en) * 2008-04-24 2016-07-12 Dyax Corp. Libraries of genetic packages comprising novel HC CDR1, CDR2, and CDR3 and novel LC CDR1, CDR2, and CDR3 designs
PT2328616E (pt) 2008-08-05 2015-08-26 Novartis Ag Composições e métodos para anticorpos dirigidos à proteína c5 do complemento
US9023594B2 (en) 2008-09-05 2015-05-05 President And Fellows Of Harvard College Continuous directed evolution of proteins and nucleic acids
WO2010079189A1 (en) 2009-01-09 2010-07-15 Morphosys Ag Display vectors and methods and uses thereof
TWI480050B (zh) 2009-02-10 2015-04-11 Daiichi Sankyo Co Ltd 抗－ｍｓｔ１ｒ抗體及其用途
EP3275900A1 (en) 2009-04-27 2018-01-31 Novartis AG Compositions and methods for increasing muscle growth
CA2759942A1 (en) 2009-04-27 2010-10-07 Novartis Ag Composition and methods of use for therapeutic antibodies specific for the il-12 receptore betai subunit
UY32560A (es) 2009-04-29 2010-11-30 Bayer Schering Pharma Ag Inmunoconjugados de antimesotelina y usos de los mismos
JP2012525134A (ja) * 2009-04-30 2012-10-22 サイトス バイオテクノロジー アーゲー インフルエンザ赤血球凝集素の組成物とその使用
AU2010252939B2 (en) 2009-05-29 2014-06-26 Morphosys Ag A collection and methods for its use
WO2011021146A1 (en) 2009-08-20 2011-02-24 Pfizer Inc. Osteopontin antibodies
AU2010291902A1 (en) * 2009-09-14 2012-04-05 Dyax Corp. Libraries of genetic packages comprising novel HC CDR3 designs
WO2011035205A2 (en) 2009-09-18 2011-03-24 Calmune Corporation Antibodies against candida, collections thereof and methods of use
JP5850846B2 (ja) 2009-11-17 2016-02-03 ヤンセン バイオテツク，インコーポレーテツド 繊維状ファージ上でのジスルフィド結合二量体タンパク質の提示
MY159680A (en) 2009-11-17 2017-01-13 Janssen Biotech Inc Improved bacterial membrane protein secrection
WO2011092313A1 (en) 2010-01-29 2011-08-04 Morphosys Ag Rodent combinatorial antibody libraries
CA2798390A1 (en) 2010-05-06 2011-11-10 Novartis Ag Compositions and methods of use for therapeutic low density lipoprotein - related protein 6 (lrp6) multivalent antibodies
EP2566892B1 (en) 2010-05-06 2017-12-20 Novartis AG Compositions and methods of use for therapeutic low density lipoprotein-related protein 6 (lrp6) antibodies
JP6266343B2 (ja) 2010-07-16 2018-01-24 アディマブ， エルエルシー 抗体ライブラリー
MY162825A (en) 2010-08-20 2017-07-31 Novartis Ag Antibodies for epidermal growth factor receptor 3 (her3)
PH12020550156A1 (en) 2010-09-09 2024-01-15 Pfizer 4-1bb binding molecules
CN103237813A (zh) 2010-10-05 2013-08-07 第一三共株式会社 靶向破骨细胞相关蛋白涎免凝集素-15的抗体
EP2640742B1 (en) 2010-11-19 2018-08-15 MorphoSys AG A collection of antibody sequences its use
AU2011348204B2 (en) 2010-12-22 2017-03-02 President And Fellows Of Harvard College Continuous directed evolution
EP2731970B1 (en) 2011-07-15 2018-11-28 MorphoSys AG Antibodies that are cross-reactive for macrophage migration inhibitory factor (mif) and d-dopachrome tautomerase (d-dt)
AU2012324895B2 (en) 2011-10-19 2017-03-16 Galapagos Nv Antagonists of IL17C for the treatment of inflammatory disorders
WO2013084147A2 (en) 2011-12-05 2013-06-13 Novartis Ag Antibodies for epidermal growth factor receptor 3 (her3)
US20130273029A1 (en) 2011-12-05 2013-10-17 Novartis Ag Antibodies for epidermal growth factor receptor 3 (her3) directed to domain ii of her3
CA2861137C (en) 2012-02-03 2022-03-22 The Governors Of The University Of Alberta Method of quantifying peptide-derivative libraries using phage display
WO2013174003A1 (en) 2012-05-24 2013-11-28 Mountgate Group Limited Compositions and methods related to prevention and treatment of rabies infection
KR102410763B1 (ko) 2012-08-17 2022-06-20 모르포시스 아게 복합체-특이적 항체 및 항체 단편 및 그의 용도
JOP20200308A1 (ar) 2012-09-07 2017-06-16 Novartis Ag جزيئات إرتباط il-18
US9428577B2 (en) 2012-11-09 2016-08-30 Pfizer Inc. Platelet-derived growth factor B specific antibodies and compositions and uses thereof
CA2890483A1 (en) 2012-11-09 2014-05-15 Robert ARCH Platelet-derived growth factor b specific antibodies and compositions and uses thereof
EP2935324B1 (en) 2012-12-20 2019-10-23 MorphoSys AG Anti-staphylococcal antibodies
EP2970479B1 (en) 2013-03-14 2019-04-24 Novartis AG Antibodies against notch 3
EA035253B1 (ru) 2013-03-15 2020-05-21 Новартис Аг Лекарственные конъюгаты антител
EP2984106B1 (en) 2013-04-12 2019-03-06 MorphoSys AG Antibodies targeting m-csf
US20160060347A1 (en) 2013-04-17 2016-03-03 Morphosys Ag Antibodies targeting specifically human cxcr2
PT3083671T (pt) 2013-12-20 2020-12-24 Hutchinson Fred Cancer Res Moléculas efetoras quiméricas etiquetadas e recetores destas
WO2015134121A2 (en) 2014-01-20 2015-09-11 President And Fellows Of Harvard College Negative selection and stringency modulation in continuous evolution systems
CA2942433C (en) 2014-03-14 2023-08-01 Immunocore Limited Tcr libraries
US10786578B2 (en) 2014-08-05 2020-09-29 Novartis Ag CKIT antibody drug conjugates
US10920208B2 (en) 2014-10-22 2021-02-16 President And Fellows Of Harvard College Evolution of proteases
EA201791050A1 (ru) 2014-11-14 2017-09-29 Новартис Аг Конъюгаты антител и лекарственных средств
JP2018518152A (ja) 2015-03-27 2018-07-12 ユニバーシティ オブ サザン カリフォルニア 充実性腫瘍を処置するためのｌｈｒに指向されたｃａｒ ｔ細胞治療
US11299729B2 (en) 2015-04-17 2022-04-12 President And Fellows Of Harvard College Vector-based mutagenesis system
US11827904B2 (en) 2015-04-29 2023-11-28 Fred Hutchinson Cancer Center Modified stem cells and uses thereof
US20180355318A1 (en) * 2015-04-29 2018-12-13 Fred Hutchinson Cancer Research Center Modified hematopoietic stem/progenitor and non-t effector cells, and uses thereof
EP3095465A1 (en) 2015-05-19 2016-11-23 U3 Pharma GmbH Combination of fgfr4-inhibitor and bile acid sequestrant
CA2987992A1 (en) 2015-06-04 2016-12-08 University Of Southern California Lym-1 and lym-2 targeted car cell immunotherapy
EA201792561A1 (ru) 2015-06-05 2018-04-30 Новартис Аг Антитела, нацеленные на морфогенетический белок кости 9 (bmp9), и способы их применения
JOP20200312A1 (ar) 2015-06-26 2017-06-16 Novartis Ag الأجسام المضادة للعامل xi وطرق الاستخدام
US10392674B2 (en) 2015-07-22 2019-08-27 President And Fellows Of Harvard College Evolution of site-specific recombinases
US11524983B2 (en) 2015-07-23 2022-12-13 President And Fellows Of Harvard College Evolution of Bt toxins
US10612011B2 (en) 2015-07-30 2020-04-07 President And Fellows Of Harvard College Evolution of TALENs
EA038332B1 (ru) 2015-09-09 2021-08-10 Новартис Аг Молекулы, связывающиеся с тимусным стромальным лимфопоэтином (tslp), и способы применения таких молекул
CU24533B1 (es) 2015-09-09 2021-07-02 Novartis Ag Anticuerpos o fragmentos de los mismos que se unen a linfopoyetina estromal tímica (tslp) y composiciones farmacéuticas de los mismos
GB201516275D0 (en) 2015-09-15 2015-10-28 Adaptimmune Ltd And Immunocore Ltd TCR Libraries
GB201516272D0 (en) 2015-09-15 2015-10-28 Adaptimmune Ltd And Immunocore Ltd TCR Libraries
GB201516277D0 (en) 2015-09-15 2015-10-28 Adaptimmune Ltd And Immunocore Ltd TCR libraries
GB201516270D0 (en) 2015-09-15 2015-10-28 Adaptimmune Ltd And Immunocore Ltd TCR Libraries
GB201516265D0 (en) 2015-09-15 2015-10-28 Adaptimmune Ltd And Immunocore Ltd TCR Libraries
GB201516269D0 (en) 2015-09-15 2015-10-28 Adaptimmune Ltd And Immunocore Ltd TCR Libraries
GB201516274D0 (en) 2015-09-15 2015-10-28 Adaptimmune Ltd And Immunocore Ltd TCR Libraries
HK1258921A1 (zh) 2015-09-23 2019-11-22 Cytoimmune Therapeutics, Inc. Flt3 定向 car 细胞免疫疗法
EP3365356B1 (en) 2015-10-23 2023-06-28 President and Fellows of Harvard College Nucleobase editors and uses thereof
EA201891724A1 (ru) 2016-02-17 2019-01-31 Новартис Аг Антитела к tgf-бета2
EP3416983B1 (en) 2016-02-19 2021-04-07 MorphoSys AG Antibodies for il-17c
TW201802121A (zh) 2016-05-25 2018-01-16 諾華公司 抗因子XI/XIa抗體之逆轉結合劑及其用途
EP3538552B1 (en) 2016-11-14 2023-09-13 MorphoSys AG Fab molecules with a rodent hinge region and a non-rodent ch1 region
WO2018229715A1 (en) 2017-06-16 2018-12-20 Novartis Ag Compositions comprising anti-cd32b antibodies and methods of use thereof
WO2019010164A1 (en) 2017-07-06 2019-01-10 President And Fellows Of Harvard College Evolution of trna synthetases
EP3444275A1 (en) 2017-08-16 2019-02-20 Exiris S.r.l. Monoclonal antibody anti-fgfr4
EP3673059A4 (en) 2017-08-25 2021-09-01 President And Fellows Of Harvard College EVOLUTION OF BONT PEPTIDASES
US11624130B2 (en) 2017-09-18 2023-04-11 President And Fellows Of Harvard College Continuous evolution for stabilized proteins
CN111587123A (zh) 2017-11-09 2020-08-25 品通治疗有限公司 用于生成和使用人源化构象特异性磷酸化的τ抗体的方法和组合物
WO2019102353A1 (en) 2017-11-22 2019-05-31 Novartis Ag Reversal binding agents for anti-factor xi/xia antibodies and uses thereof
US11453883B2 (en) 2018-04-05 2022-09-27 Bio-Rad Abd Serotec Gmbh Display systems for proteins of interest
EP3793596A1 (en) 2018-05-16 2021-03-24 MorphoSys AG Antibodies targeting glycoprotein vi
US11913044B2 (en) 2018-06-14 2024-02-27 President And Fellows Of Harvard College Evolution of cytidine deaminases
US12129298B2 (en) 2018-06-21 2024-10-29 Daiichi Sankyo Company, Limited Compositions including CD3 antigen binding fragments and uses thereof
EP3827116A4 (en) 2018-07-23 2022-05-11 The Governors of the University of Alberta Genetically-encoded bicyclic peptide libraries
UY38407A (es) 2018-10-15 2020-05-29 Novartis Ag Anticuerpos estabilizadores de trem2
CA3133074A1 (en) 2019-03-11 2020-09-17 Memorial Sloan Kettering Cancer Center Cd22 antibodies and methods of using the same
BR112021017860A2 (pt) 2019-03-14 2021-12-07 Morphosys Ag Anticorpo ou fragmento de anticorpo isolado específico para c5ar de humano, composição de ácido nucleico, composição de vetor, célula hospedeira e composição farmacêutica
TW202124446A (zh) 2019-09-18 2021-07-01 瑞士商諾華公司 與ｅｎｔｐｄ２抗體之組合療法
AU2021308712B2 (en) 2020-07-16 2025-10-09 Novartis Ag Anti-betacellulin antibodies, fragments thereof, and multi-specific binding molecules
US20230357398A1 (en) 2020-09-24 2023-11-09 Morphosys Ag Novel human antibodies binding to human cd3 epsilon
AU2022207708A1 (en) 2021-01-13 2023-07-27 Daiichi Sankyo Company, Limited Antibody-pyrrolobenzodiazepine derivative conjugate
CN117425500A (zh) 2021-01-13 2024-01-19 纪念斯隆凯特琳癌症中心 抗dll3抗体-药物缀合物
WO2023032955A1 (ja) 2021-08-31 2023-03-09 大正製薬株式会社 抗成長ホルモン抗体
IL315591A (en) 2022-03-22 2024-11-01 Morphosys Ag Nonimmune antibodies specific for CD3
GB202204159D0 (en) 2022-03-24 2022-05-11 Heptares Therapeutics Ltd Antibodies
WO2024236163A1 (en) 2023-05-17 2024-11-21 Morphosys Ag T cell receptor beta constant region 2 (trbc2) antibodies
WO2025003511A1 (en) 2023-06-30 2025-01-02 Morphosys Ag Dual-targeting of flt3 and cd123 co-expressing tumor cells by functional complementation of cycat® halfbody molecules
WO2025082777A1 (en) 2023-10-17 2025-04-24 Morphosys Ag Dual-targeting of muc16 and mesothelin co-expressing tumor cells by functional complementation of cycat® halfbody molecules

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE8203855D0 (sv) 1982-06-21 1982-06-21 Astra Laekemedel Ab Novel derivatives of guanine i
DE3852304T3 (de) 1987-03-02 1999-07-01 Enzon Labs Inc., Piscataway, N.J. Organismus als Träger für "Single Chain Antibody Domain (SCAD)".
AU4308689A (en) 1988-09-02 1990-04-02 Protein Engineering Corporation Generation and selection of recombinant varied binding proteins
US5747334A (en) * 1990-02-15 1998-05-05 The University Of North Carolina At Chapel Hill Random peptide library
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
US5723286A (en) 1990-06-20 1998-03-03 Affymax Technologies N.V. Peptide library and screening systems
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5770434A (en) * 1990-09-28 1998-06-23 Ixsys Incorporated Soluble peptides having constrained, secondary conformation in solution and method of making same
US5871974A (en) * 1990-09-28 1999-02-16 Ixsys Inc. Surface expression libraries of heteromeric receptors
WO1992009690A2 (en) 1990-12-03 1992-06-11 Genentech, Inc. Enrichment method for variant proteins with altered binding properties
GB9114003D0 (en) * 1991-06-28 1991-08-14 Mastico Robert A Chimaeric protein
GB9213601D0 (en) * 1992-06-26 1992-08-12 Mastico Robert A Protein based delivery system
CA2115811A1 (en) * 1993-02-17 1994-08-18 Claus Krebber A method for in vivo selection of ligand-binding proteins
GB9313509D0 (en) * 1993-06-30 1993-08-11 Medical Res Council Chemisynthetic libraries
US6309642B1 (en) * 1997-04-28 2001-10-30 The Research And Development Institute, Inc. Peptides which mimic candida carbohydrate epitopes and their use in a vaccine
US6341256B1 (en) * 1995-03-31 2002-01-22 Curagen Corporation Consensus configurational bias Monte Carlo method and system for pharmacophore structure determination
CA2229043C (en) 1995-08-18 2016-06-07 Morphosys Gesellschaft Fur Proteinoptimierung Mbh Protein/(poly)peptide libraries
GB9608540D0 (en) * 1996-04-25 1996-07-03 Medical Res Council Isolation of enzymes
JP2002501721A (ja) * 1997-08-01 2002-01-22 モルフォシス・アクチェンゲゼルシャフト 多量体（ポリ）ペプチドコンプレックスのメンバーをコードする核酸配列を同定するための新規方法およびファージ
JP4493846B2 (ja) 1998-05-13 2010-06-30 ドマンティス リミテッド 選択系

Also Published As

Publication number Publication date
US20070292947A1 (en) 2007-12-20
CA2347973C (en) 2010-06-22
US20020034733A1 (en) 2002-03-21
EP1990409A2 (en) 2008-11-12
NO20011386D0 (no) 2001-03-19
PT1144607E (pt) 2009-04-22
IL142025A (en) 2009-12-24
ATE417925T1 (de) 2009-01-15
US7785859B2 (en) 2010-08-31
JP4312403B2 (ja) 2009-08-12
EP1144607B1 (en) 2008-12-17
DK1144607T5 (da) 2009-10-05
US20050058984A1 (en) 2005-03-17
EP1144607A2 (en) 2001-10-17
EP1990409A3 (en) 2011-05-18
AU5986400A (en) 2001-02-05
WO2001005950A2 (en) 2001-01-25
AU781396B2 (en) 2005-05-19
US6753136B2 (en) 2004-06-22
NO20011386L (no) 2001-05-18
CA2347973A1 (en) 2001-01-25
IL142025A0 (en) 2002-03-10
DK1144607T3 (da) 2009-08-24
WO2001005950A3 (en) 2001-08-02
NO331199B1 (no) 2011-10-31
ES2327382T3 (es) 2009-10-29
JP2003505025A (ja) 2003-02-12

Similar Documents

Publication Publication Date Title
ATE417925T1 (de) Verfahren zur präsentation von (poly)peptiden/proteinen auf bakteriophagenpartikeln via disulfidbindungen
DE60040333D1 (de) Verfahren zur acylierung von peptiden und proteinen
DE69739035D1 (de) Zusammensetzungen und Methoden zur Behandlung von Infektionen unter Verwendung von Indolicidinanalogen
PT929574E (pt) Moduladores da agregacao de peptidos beta-amiloides compreendendo d-aminoacidos
DE60031030D1 (de) Verfahren zur Identifizierung von Peptiden und Proteinen mittels Massenspektromterie
PT662827E (pt) Metodos de diagnostico e composicoes farmaceuticas a base de proteinas notch e acidos nucleicos
MX9305729A (es) Formulas de proteinas de liberacion sostenida.
DE60026452D1 (de) Verfahren zur Identifizierung von Peptidensequenzen und Proteinensequenzen mittels Massenspektromterie
DE69823046D1 (de) Praktische in vitro sialylierung von rekombinanten glykpproteinen
WO2002002627A3 (en) Interferon-like protein zcyto21
DE3856059D1 (de) Peptid-Determinante mit Einfluss auf die Immunität
ATE326984T1 (de) Verfahren zur verbindung von molekularen substanzen
ATE236984T1 (de) Verfahren zur herstellung von hydrophoben polypeptiden, proteinen und peptiden
DE60023860D1 (de) Verfahren zur herstellung von rekombinanten peptiden
DE69715181D1 (de) Peptid der löslichen form von acetylcholinesterase mit aktivität als calciumkanalmodulator
DE602004032345D1 (de) Reagenzien und verfahren zur bildung von disulfid-bindungen und glykosylierung von proteinen
ATE448241T1 (de) Verfahren zur reinigung stark anionischer proteine
ATE397081T1 (de) Erhöhte expression von proteinen mittels gfp
ATE290088T1 (de) Verfahren zur spaltung eines chimeren proteins mittels eines 'processing'-enzyms
DE59004279D1 (de) Verfahren zur C-terminalen Modifizierung von Proteinen.
ATE417105T1 (de) Spleissvariante des kopftrauma induzierten zytoplasmatischen calcium-bindenden proteins

Legal Events

Date Code Title Description
8364 No opposition during term of opposition